Mestag teams up with Janssen in inflammatory disease

18 May 2021

UK breakthrough inflammatory disease and immuno-oncology company Mestag Therapeutics has announced a target discovery, option and license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ).

The agreement, supported by Johnson & Johnson Innovation, the US healthcare giant's strategic venture capital arm, will leverage Mestag’s specialist fibroblast sub-population biology platform and data analytics to identify new therapeutic targets in the inflammatory disease space.

Under the terms of the agreement, Mestag will interrogate fibroblast subpopulations across diseases and their interactions with key aspects of the immune system.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK